Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | TOP2A | P11388 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | STK17B | O94768 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30128910 | 0.79 | TOP2A (0.53) | MAPTTOP2AKMT2APOLBALDH1A1 | |
| SCHEMBL30128624 | 0.79 | ABL1 (0.55) | MAPTAPPTOP2AKMT2AHPGD | |
| Ethyl Vanillin SCHEMBL7523394 | 0.77 | ALDH1A1 (0.72) | MAPTAPPTOP2AKMT2AHPGD | |
| SCHEMBL30128631 | 0.76 | ALDH1A1 (0.60) | MAPTTOP2AKMT2AHPGDALDH1A1 | |
| SCHEMBL29185902 | 0.73 | POLB (0.47) | MAPTKMT2APOLBHPGDALDH1A1 | |
| SCHEMBL30128764 | 0.72 | ALDH1A1 (0.62) | MAPTTOP2AKMT2AHPGDALDH1A1 | |
| SCHEMBL18308933 | 0.72 | MAPT (0.51) | MAPTAPPTOP2AKMT2APOLB | |
| SCHEMBL18837421 | 0.72 | MAPT (0.51) | MAPTAPPTOP2AKMT2APOLB | |
| SCHEMBL18837422 | 0.72 | MAPT (0.51) | MAPTAPPTOP2AKMT2APOLB | |
| SCHEMBL30128781 | 0.71 | ALDH1A1 (0.41) | MAPTAPPTOP2AKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294470-A1 | FRAGRANCE COMPOUNDS | GIVAUDAN SA (CH) | 2024-09-05 | — | — | US | disclosed |
| EP-4355728-A1 | FRAGRANCE COMPOUNDS | Givaudan SA (CH) | 2024-04-24 | — | — | EP | disclosed |
| WO-2022263605-A1 | FRAGRANCE COMPOUNDS | GIVAUDAN SA (CH) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022261956-A1 | FRAGRANCE COMPOUNDS | GIVAUDAN SA (CH) | 2022-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294470-A1 | FRAGRANCE COMPOUNDS | FASN, FAAH2, FADS2 | MAPT 3089/4885APP 1353/4885TOP2A 2118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.